+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Acne Vulgaris (Dermatology) - Drugs In Development, 2021

  • PDF Icon

    Report

  • 252 Pages
  • July 2021
  • Region: Global
  • Global Markets Direct
  • ID: 5402599
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Acne Vulgaris - Drugs In Development, 2021, provides an overview of the Acne Vulgaris (Dermatology) pipeline landscape.

Acne vulgaris is a chronic skin disease involving blockage and inflammation of pilosebaceous follicles. Symptoms include crusting of skin bumps, cysts, papules (small red bumps), scarring of the skin and redness around the skin eruptions. Risk factors include adolescence, hair gels or oil-based cosmetics, sports equipment such as helmet straps rubbing and occluding skin. Treatment includes antibiotics.

Report Highlights


The publisher's Pharmaceutical and Healthcare latest pipeline guide Acne Vulgaris - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Acne Vulgaris (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acne Vulgaris (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Acne Vulgaris and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 7, 18, 6, 1, 19, 5 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.

Acne Vulgaris (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acne Vulgaris (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Acne Vulgaris (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acne Vulgaris (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acne Vulgaris (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acne Vulgaris (Dermatology)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acne Vulgaris (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acne Vulgaris (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction
Acne Vulgaris - Overview
  • Acne Vulgaris - Therapeutics Development
Acne Vulgaris - Therapeutics AssessmentAcne Vulgaris - Companies Involved in Therapeutics DevelopmentAcne Vulgaris - Drug ProfilesAcne Vulgaris - Dormant ProjectsAcne Vulgaris - Discontinued ProductsAcne Vulgaris - Product Development MilestonesAppendix
List of Tables
  • Number of Products under Development for Acne Vulgaris, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Acne Vulgaris - Pipeline by Akaal Pharma Pty Ltd, 2021
  • Acne Vulgaris - Pipeline by Allianz Pharmascience Ltd (Inactive), 2021
  • Acne Vulgaris - Pipeline by AMD Therapeutics LLC, 2021
  • Acne Vulgaris - Pipeline by Amgen Inc, 2021
  • Acne Vulgaris - Pipeline by AnaptysBio Inc, 2021
  • Acne Vulgaris - Pipeline by AOBiome LLC, 2021
  • Acne Vulgaris - Pipeline by Atacama Therapeutics Inc, 2021
  • Acne Vulgaris - Pipeline by Attillaps Holdings Inc, 2021
  • Acne Vulgaris - Pipeline by Avecho Biotechnology Ltd, 2021
  • Acne Vulgaris - Pipeline by Avicanna Inc, 2021
  • Acne Vulgaris - Pipeline by Bausch Health Companies Inc, 2021
  • Acne Vulgaris - Pipeline by Biofrontera AG, 2021
  • Acne Vulgaris - Pipeline by Biozeus Pharmaceutical SA, 2021
  • Acne Vulgaris - Pipeline by Boston Pharmaceuticals Inc, 2021
  • Acne Vulgaris - Pipeline by Botanix Pharmaceuticals Ltd, 2021
  • Acne Vulgaris - Pipeline by Boulos and Cooper Pharmaceuticals Pty Ltd, 2021
  • Acne Vulgaris - Pipeline by Cassiopea SpA, 2021
  • Acne Vulgaris - Pipeline by Cellix Bio Pvt Ltd, 2021
  • Acne Vulgaris - Pipeline by Claritas Pharmaceuticals Inc, 2021
  • Acne Vulgaris - Pipeline by Clinuvel Pharmaceuticals Ltd, 2021
  • Acne Vulgaris - Pipeline by Cutanea Life Sciences Inc, 2021
  • Acne Vulgaris - Pipeline by Daewoong Pharmaceutical Co Ltd, 2021
  • Acne Vulgaris - Pipeline by Dermata Therapeutics Inc, 2021
  • Acne Vulgaris - Pipeline by Dermavant Sciences Inc, 2021
  • Acne Vulgaris - Pipeline by Devonian Health Group Inc, 2021
  • Acne Vulgaris - Pipeline by Eligo Bioscience SA, 2021
  • Acne Vulgaris - Pipeline by ELORAC Inc, 2021
  • Acne Vulgaris - Pipeline by Hoth Therapeutics Inc, 2021
  • Acne Vulgaris - Pipeline by Innovation Pharmaceuticals Inc, 2021
  • Acne Vulgaris - Pipeline by Kintor Pharmaceutical Ltd, 2021
  • Acne Vulgaris - Pipeline by Lee's Pharmaceutical Holdings Ltd, 2021
  • Acne Vulgaris - Pipeline by Madam Therapeutics BV, 2021
  • Acne Vulgaris - Pipeline by Maruho Co Ltd, 2021
  • Acne Vulgaris - Pipeline by Matrisys Bioscience Inc, 2021
  • Acne Vulgaris - Pipeline by Melinta Therapeutics Inc, 2021
  • Acne Vulgaris - Pipeline by Naked Biome Inc, 2021
  • Acne Vulgaris - Pipeline by Novabiotics Ltd, 2021
  • Acne Vulgaris - Pipeline by Novartis AG, 2021
  • Acne Vulgaris - Pipeline by Origimm Biotechnology GmbH, 2021
  • Acne Vulgaris - Pipeline by Ortho Dermatologics Inc, 2021
  • Acne Vulgaris - Pipeline by Paratek Pharmaceuticals Inc, 2021
  • Acne Vulgaris - Pipeline by Phagelux Inc, 2021
  • Acne Vulgaris - Pipeline by PHI Therapeutics Inc, 2021
  • Acne Vulgaris - Pipeline by Promius Pharma LLC, 2021
  • Acne Vulgaris - Pipeline by Provectus Biopharmaceuticals Inc, 2021
  • Acne Vulgaris - Pipeline by Revive Therapeutics Ltd, 2021
  • Acne Vulgaris - Pipeline by Riptide Bioscience Inc, 2021
  • Acne Vulgaris - Pipeline by SaNOtize Research and Development Corp, 2021
  • Acne Vulgaris - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, 2021
  • Acne Vulgaris - Pipeline by Timber Pharmaceuticals Inc, 2021
  • Acne Vulgaris - Pipeline by Verge Therapeutics Inc, 2021
  • Acne Vulgaris - Pipeline by VYNE Therapeutics Inc, 2021
  • Acne Vulgaris - Pipeline by Vyome Therapeutics Inc, 2021
  • Acne Vulgaris - Dormant Projects, 2021
  • Acne Vulgaris - Discontinued Products, 2021

List of Figures
  • Number of Products under Development for Acne Vulgaris, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Akaal Pharma Pty Ltd
  • Allianz Pharmascience Ltd (Inactive)
  • AMD Therapeutics LLC
  • Amgen Inc
  • AnaptysBio Inc
  • AOBiome LLC
  • Atacama Therapeutics Inc
  • Attillaps Holdings Inc
  • Avecho Biotechnology Ltd
  • Avicanna Inc
  • Bausch Health Companies Inc
  • Biofrontera AG
  • Biozeus Pharmaceutical SA
  • Boston Pharmaceuticals Inc
  • Botanix Pharmaceuticals Ltd
  • Boulos and Cooper Pharmaceuticals Pty Ltd
  • Cassiopea SpA
  • Cellix Bio Pvt Ltd
  • Claritas Pharmaceuticals Inc
  • Clinuvel Pharmaceuticals Ltd
  • Cutanea Life Sciences Inc
  • Daewoong Pharmaceutical Co Ltd
  • Dermata Therapeutics Inc
  • Dermavant Sciences Inc
  • Devonian Health Group Inc
  • Eligo Bioscience SA
  • ELORAC Inc
  • Hoth Therapeutics Inc
  • Innovation Pharmaceuticals Inc
  • Kintor Pharmaceutical Ltd
  • Lee's Pharmaceutical Holdings Ltd
  • Madam Therapeutics BV
  • Maruho Co Ltd
  • Matrisys Bioscience Inc
  • Melinta Therapeutics Inc
  • Naked Biome Inc
  • Novabiotics Ltd
  • Novartis AG
  • Origimm Biotechnology GmbH
  • Ortho Dermatologics Inc
  • Paratek Pharmaceuticals Inc
  • Phagelux Inc
  • PHI Therapeutics Inc
  • Promius Pharma LLC
  • Provectus Biopharmaceuticals Inc
  • Revive Therapeutics Ltd
  • Riptide Bioscience Inc
  • SaNOtize Research and Development Corp
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • Timber Pharmaceuticals Inc
  • Verge Therapeutics Inc
  • VYNE Therapeutics Inc
  • Vyome Therapeutics Inc